Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $29.75 Average Target Price from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $29.75.

A number of equities analysts have commented on the stock. Royal Bank Of Canada cut shares of Jasper Therapeutics from an “outperform” rating to a “sector perform” rating and set a $5.00 price objective for the company. in a research note on Tuesday, July 8th. BTIG Research lowered their target price on shares of Jasper Therapeutics from $64.00 to $20.00 and set a “buy” rating for the company in a report on Monday, July 7th. BMO Capital Markets restated a “market perform” rating on shares of Jasper Therapeutics in a report on Tuesday, July 8th. William Blair restated a “market perform” rating on shares of Jasper Therapeutics in a report on Monday, July 7th. Finally, JMP Securities lowered their target price on shares of Jasper Therapeutics from $70.00 to $12.00 and set a “market outperform” rating for the company in a report on Tuesday, July 8th.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors have recently made changes to their positions in the stock. Simplify Asset Management Inc. acquired a new position in shares of Jasper Therapeutics during the 4th quarter valued at about $428,000. EntryPoint Capital LLC acquired a new position in shares of Jasper Therapeutics during the 4th quarter valued at about $223,000. Schroder Investment Management Group acquired a new position in shares of Jasper Therapeutics during the 4th quarter valued at about $1,237,000. Wellington Management Group LLP increased its stake in shares of Jasper Therapeutics by 13.9% during the 4th quarter. Wellington Management Group LLP now owns 27,069 shares of the company’s stock valued at $579,000 after acquiring an additional 3,310 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after acquiring an additional 3,828 shares during the last quarter. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Jasper Therapeutics Stock Performance

Shares of JSPR opened at $3.15 on Friday. The firm’s 50-day simple moving average is $4.98 and its two-hundred day simple moving average is $5.35. Jasper Therapeutics has a fifty-two week low of $2.27 and a fifty-two week high of $26.05. The stock has a market cap of $47.31 million, a PE ratio of -0.60 and a beta of 2.69.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Monday, May 12th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.24). Equities research analysts predict that Jasper Therapeutics will post -4.47 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.